Scott I. Hauenstein, Ph.D.
Affiliations: | 2007 | Chemistry | University of California, Santa Barbara, Santa Barbara, CA, United States |
Area:
BiochemistryGoogle:
"Scott Hauenstein"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| John J. Perona | grad student | 2007 | UC Santa Barbara | |
| (Evolution of cysteinyl -tRNA(Cys) formation within the three domains of life.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yarur AJ, Jain A, Hauenstein SI, et al. (2016) Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases |
| Baert F, Kondragunta V, Lockton S, et al. (2015) Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut |
| Zitomersky NL, Atkinson BJ, Fournier K, et al. (2015) Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflammatory Bowel Diseases. 21: 307-14 |
| Yarur AJ, Kubiliun MJ, Czul F, et al. (2015) Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 13: 1118-24.e3 |
| Papamichael K, Vande Casteele N, Gils A, et al. (2015) Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 13: 1103-10 |
| Papamichael K, Claes K, de Bruyn M, et al. (2015) Tu1344 Serology Panel for Prediction of Relapse After Discontinuation of Infliximab in Patients With Crohn's Disease Achieving Clinical Remission Gastroenterology. 148: S-865 |
| Vande Casteele N, Khanna R, Levesque BG, et al. (2014) The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut |
| Baert F, Drobne D, Gils A, et al. (2014) Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 12: 1474-81.e2; quiz e91 |
| Yarur A, Hauenstein S, Czul F, et al. (2014) Serum Certolizumab Pegol Levels and Antibodies to Certolizumab Pegol Are Associated With C-Reactive Protein Levels in Patients With Crohn’s Disease American Journal of Gastroenterology. 109: S523 |
| Bruyn Md, Bessissow T, Billiet T, et al. (2014) DOP063 Biomarker panel for prediction of mucosal healing in patients with Crohn's disease under infliximab therapy Journal of Crohn's and Colitis. 8 |